Last updated on August 2017

Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A


Brief description of study

This trial is conducted in China. The aim of this trial is to evaluate the clinical efficacy of turoctocog alfa in treatment of bleeding episodes in Chinese patients with severe haemophilia A (FVIII≤1%).

Clinical Study Identifier: NCT02938585

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Novo Nordisk

Novo Nordisk Investigational Site
Beijing, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Chonqqing, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Fuzhou, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Guangzhou, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Guiyang, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Wuhan, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Xining, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Shanghai, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Tianjing, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Kunming, China
  Connect »

Novo Nordisk

Novo Nordisk Investigational Site
Hangzhou, China
  Connect »